Pharmacokinetic study of pegylated liposomal CKD-602 (S-CKD602) in patients with advanced malignancies.

@article{Zamboni2009PharmacokineticSO,
  title={Pharmacokinetic study of pegylated liposomal CKD-602 (S-CKD602) in patients with advanced malignancies.},
  author={William C. Zamboni and Sandra A. Strychor and Lauren J. Maruca and Suresh S Ramalingam and Beth A. Zamboni and Hulin Wu and David M. Friedland and Robert Edwards and Ronald G. Stoller and Chandra Prakash Belani and Ramesh K. Ramanathan},
  journal={Clinical pharmacology and therapeutics},
  year={2009},
  volume={86 5},
  pages={519-26}
}
S-CKD602 is a pegylated liposomal formulation of CKD-602. This study is the first to evaluate the factors affecting the high interpatient variability in the pharmacokinetic disposition of S-CKD602. S-CKD602 was administered intravenously (i.v.) every 3 weeks as part of a phase I study. Pharmacokinetics studies of the liposomal encapsulated and released CKD-602 in plasma were performed. The pharmacokinetic variability of S-CKD602 is associated with both linear and nonlinear clearances. Patients… CONTINUE READING

From This Paper

Figures, tables, and topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 13 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 31 references

A phase I and pharmacologic study of belotecan in combination with cisplatin in patients with previously untreated extensive-stage disease small cell lung cancer

  • D Lee
  • Clin. Cancer Res
  • 2008

Age-related effects on the pharmacodynamic (PD) relationship between STEALTH® liposomal CKD-602 (S-CKD602) and monocytes in patients with refractory solid tumors

  • Maruca, L.J
  • J. Clin. Oncol. ASCO Annual Meeting Proceedings
  • 2007

Fat and skeletal muscle disposition of STEALTH® liposomal CKD-602 (S-CKD602) and non-liposomal CKD-602, a camptothecin analogue, in SCID mice

  • Zamboni, W.C
  • Proc. Am. Assoc. Cancer Res
  • 2007

methods to evaluate the encapsulated and released drug in plasma and tumor and phenotypic probes for pharmacokinetic (PK) and pharmacodynamic (PD) disposition

  • Zamboni, W. C. et al. The development of liposomal, nanoparticle anticancer agents
  • NSTI Annual Conference Proceedings of…
  • 2007

Plasma and tumor disposition of STEALTH® liposomal CKD-602 (S-CKD602) and non-liposomal CKD-602, a camptothecin analogue, in mice bearing A375 human melanoma xenografts

  • S Strychor
  • Proc. Am. Assoc. Cancer Res
  • 2006

Relationship between the plasma and tumor disposition of STEALTH® liposomal CKD-602 and macrophages/dendritic cells (MDC) in mice bearing human tumor xenografts

  • Zamboni, W.C
  • Proc. Am. Assoc. Cancer Res
  • 2006

Final results of a phase I study of liposome encapsulated SN - 38 ( LE - SN 38 ) : safety , pharmacogenomics , pharmacokinetics , and tumor response

  • E. H. Kraut
  • J . Clin . Oncol . ASCO Annual Meeting…
  • 2005

Similar Papers

Loading similar papers…